207 related articles for article (PubMed ID: 8755816)
21. Flow cytometry beads rather than the antihuman globulin method should be used to detect HLA Class I IgG antibody (PRA) in cadaveric renal regraft candidates.
Bryan CF; McDonald SB; Baier KA; Luger AM; Aeder MI; Murillo D; Muruve NA; Nelson PW; Shield CF; Warady BA
Clin Transplant; 2002; 16 Suppl 7():15-23. PubMed ID: 12372039
[TBL] [Abstract][Full Text] [Related]
22. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection.
Supon P; Constantino D; Hao P; Cagle L; Hahn A; Conti DJ; Freed BM
Transplantation; 2001 Feb; 71(4):577-80. PubMed ID: 11258441
[TBL] [Abstract][Full Text] [Related]
24. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period.
Sánchez-Zapardiel E; Castro-Panete MJ; Castillo-Rama M; Morales P; Lora-Pablos D; Valero-Hervás D; Ruiz-García R; Apaza J; Talayero P; Andrés A; Morales JM; Paz-Artal E
Transplantation; 2013 Jul; 96(1):70-8. PubMed ID: 23624543
[TBL] [Abstract][Full Text] [Related]
25. Sensitization and sensitivity: defining the unsensitized patient.
Gebel HM; Bray RA
Transplantation; 2000 Apr; 69(7):1370-4. PubMed ID: 10798756
[TBL] [Abstract][Full Text] [Related]
26. Reactivity of twenty-two cytotoxic human monoclonal HLA antibodies towards soluble HLA class I in an enzyme-linked immunosorbent assay (PRA-STAT).
Mulder A; Kardol M; Regan J; Buelow R; Claas F
Hum Immunol; 1997; 56(1-2):106-13. PubMed ID: 9455499
[TBL] [Abstract][Full Text] [Related]
27. The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipients.
Kerman RH; Kimball P; Scheinen S; Radovancevic B; Van Buren CT; Kahan BD; Frazier OH
Transplantation; 1994 Mar; 57(6):884-8. PubMed ID: 8154036
[TBL] [Abstract][Full Text] [Related]
28. Maternal HLA panel-reactive antibodies in early gestation positively correlate with chronic chorioamnionitis: evidence in support of the chronic nature of maternal anti-fetal rejection.
Lee J; Romero R; Xu Y; Kim JS; Park JY; Kusanovic JP; Chaiworapongsa T; Hassan SS; Kim CJ
Am J Reprod Immunol; 2011 Dec; 66(6):510-26. PubMed ID: 21951517
[TBL] [Abstract][Full Text] [Related]
29. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
[TBL] [Abstract][Full Text] [Related]
30. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival.
Kerman RH; Kimball PM; Lindholm A; Van Buren CT; Katz SM; Lewis RM; McClain J; Podbielski J; Williams J; Kahan BD
Transplantation; 1993 Nov; 56(5):1242-7. PubMed ID: 8249130
[TBL] [Abstract][Full Text] [Related]
31. [Comparative evaluation of ELISA and Luminex panel reactive antibody assays for HLA alloantibody screening].
Jung S; Oh EJ; Yang CW; Ahn WS; Kim Y; Park YJ; Han K
Korean J Lab Med; 2009 Oct; 29(5):473-80. PubMed ID: 19893358
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of anti-HLA antibodies pre and post transplant.
Kerman RH; Orosz CG; Lorber MI
Am J Med Sci; 1997 May; 313(5):275-8. PubMed ID: 9145036
[TBL] [Abstract][Full Text] [Related]
33. Donor-specific HLA class I and CREG antibodies in complement-dependent cytotoxicity-negative renal transplants.
Kim Y; Yang CW; Moon IS; Kim M; Lim J; Park YJ; Han K; Oh EJ
Ann Clin Lab Sci; 2010; 40(4):330-5. PubMed ID: 20947806
[TBL] [Abstract][Full Text] [Related]
34. Antibodies against MICA antigens and kidney-transplant rejection.
Zou Y; Stastny P; Süsal C; Döhler B; Opelz G
N Engl J Med; 2007 Sep; 357(13):1293-300. PubMed ID: 17898098
[TBL] [Abstract][Full Text] [Related]
35. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival.
Pagani FD; Dyke DB; Wright S; Cody R; Aaronson KD
J Heart Lung Transplant; 2001 Jun; 20(6):646-53. PubMed ID: 11404170
[TBL] [Abstract][Full Text] [Related]
36. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
Barocci S; Valente U; Nocera A
Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of anti-HLA class I and II antibodies by flow cytometry in patients after first cadaveric kidney transplantation.
Müller-Steinhardt M; Fricke L; Kirchner H; Hoyer J; Klüter H
Clin Transplant; 2000 Feb; 14(1):85-9. PubMed ID: 10693642
[TBL] [Abstract][Full Text] [Related]
38. Long-term kidney graft survival across a positive historic but negative current sensitized cross-match.
Baron C; Pastural M; Lang P; Bentabet R; el-Kassar N; Seror T; Dahmane D; Desvaux D; Chopin D; Fruchaud G; Remy P; Grimbert P; Lepage E; Bierling P
Transplantation; 2002 Jan; 73(2):232-6. PubMed ID: 11821736
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of HLA antibodies with the PRA-STAT test. An ELISA test using soluble HLA class I molecules.
Zachary AA; Griffin J; Lucas DP; Hart JM; Leffell MS
Transplantation; 1995 Dec; 60(12):1600-6. PubMed ID: 8545897
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
